Chemical Structure and Synthesis of Ipamorelin: Properties of This Pentapeptide Research Compound | Palmetto Peptides

Chemical Structure and Synthesis of Ipamorelin: Properties of This Pentapeptide Research Compound

Research Notice: This article covers research on Ipamorelin research peptide and CJC-1295 without DAC research peptide — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

DISCLAIMER: This article is for educational and scientific research reference purposes only. Ipamorelin is not approved by the FDA for use in humans or animals. Palmetto Peptides sells Ipamorelin exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.

Last Updated: March 27, 2026 | Reading Time: Approximately 9 minutes | Author: Palmetto Peptides Research Team

Quick Answer

Ipamorelin is a synthetic pentapeptide (five-amino-acid chain) with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It incorporates two non-natural amino acids (Aib and D-2-Nal) and D-forms of two naturally occurring amino acids, along with an amide C-terminus. These structural modifications give Ipamorelin its resistance to enzymatic degradation and contribute to its selective binding at the ghrelin receptor (GHSR-1a). It is produced via solid-phase peptide synthesis (SPPS) and purified by HPLC to achieve research-grade purity of 98%+.

Introduction: Why Structure Determines Function in Peptide Research

In chemistry, structure and function are inseparable. For a research peptide like Ipamorelin, the specific arrangement of its five amino acids, including which amino acids are chosen, which are in "D" versus "L" form, and what modifications are made to the chain's ends, collectively determine:

Which receptor it binds to and with what affinity

How selectively it activates downstream signaling

How quickly enzymes in biological systems break it down

Its solubility and stability as a research reagent

Understanding Ipamorelin's chemical structure is therefore not just academic background, it is the foundation for understanding why this particular peptide behaves as it does in preclinical research models. Every structural feature has a functional consequence.

For the broader context on Ipamorelin's research applications, see the Palmetto Peptides Complete Guide to Ipamorelin.

Physicochemical Identity Reference

Full Name

Ipamorelin

CAS Number

170851-70-4

Molecular Formula

C38H49N9O5

Molecular Weight

711.87 g/mol

Amino Acid Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Peptide Length

5 residues (pentapeptide)

C-Terminus Modification

Amide (-NH2)

N-Terminus

Free (unmodified)

Appearance

White to off-white lyophilized powder

Solubility

Soluble in water and aqueous buffers

Research-Grade Purity

98%+ by HPLC

Table 1: Physicochemical identity summary for Ipamorelin research compound.

Amino Acid by Amino Acid: What Each Residue Contributes

Ipamorelin's sequence is: Aib - His - D-2-Nal - D-Phe - Lys - NH2

Let's examine each position and what it contributes to the peptide's overall properties.

Position 1: Aib (Alpha-Aminoisobutyric Acid)

What it is: Aib is a non-proteinogenic amino acid, meaning it is not encoded by the standard genetic code and does not occur in naturally produced proteins. It is structurally similar to alanine but has two methyl groups on the alpha carbon instead of the one that alanine has. This makes the alpha carbon of Aib a quaternary carbon (bonded to four non-hydrogen substituents), which has important structural consequences.

What it contributes:

The quaternary alpha carbon cannot form a planar amide bond in the same geometry as natural amino acids, which locks the local peptide backbone into restricted conformations, specifically favoring helical structures

This conformational restriction contributes to Ipamorelin's specific three-dimensional shape, influencing how it fits into the GHSR-1a receptor binding pocket

Aib-containing bonds are highly resistant to cleavage by peptidases (the enzymes that break down peptide chains in biological systems), which improves Ipamorelin's metabolic stability as a research tool

In plain terms: The Aib residue is like a molecular spacer that forces the peptide chain into a particular shape and makes it harder for biological enzymes to chop the chain apart.

Position 2: His (Histidine)

What it is: Histidine is a standard, naturally occurring amino acid used here in its normal L-form. It contains an imidazole ring as its side chain, which can interact with receptor residues through hydrogen bonding and electrostatic interactions.

Histidine is a key recognition element in the binding interaction with GHSR-1a

Comparison of Ipamorelin's sequence with other GHS peptides (like GHRP-6, which also starts with His) suggests that histidine at this position is important for initial receptor recognition

The imidazole ring can be protonated or neutral depending on pH, which affects the binding interaction under different experimental conditions

Position 3: D-2-Nal (D-2-Naphthylalanine)

What it is: This is one of the two clearly non-natural residues in Ipamorelin. 2-Naphthylalanine is an amino acid with a naphthalene ring system (a bicyclic aromatic ring, larger than the single benzene ring of phenylalanine) as its side chain. The "D" prefix means this amino acid is in the D-form (mirror image of the natural L-form).

The large, flat naphthalene ring system creates strong hydrophobic and aromatic interactions within the GHSR-1a binding pocket, contributing substantially to binding affinity

The D-configuration at this position means the naphthalene ring points in a different spatial direction than it would in the L-form, affecting the peptide's overall shape and selectivity

D-amino acids are generally resistant to cleavage by the proteases (enzymes) that degrade natural L-amino acid peptides, further contributing to metabolic stability

In plain terms: The D-2-Nal residue is a large, flat aromatic molecule that fits snugly into a complementary pocket in the receptor and resists enzymatic destruction.

Position 4: D-Phe (D-Phenylalanine)

What it is: Phenylalanine is a standard amino acid with a benzene ring side chain. The D-form used here is the mirror image of the natural L-phenylalanine.

Another aromatic residue that participates in binding interactions with GHSR-1a

The D-configuration contributes to enzymatic resistance at this peptide bond

The presence of D-Phe at this position is shared with other GHS peptides (like GHRP-6 and GHRP-2), suggesting this position is important for GHSR-1a recognition across the class

Position 5: Lys-NH2 (Lysine Amide)

What it is: Lysine is a standard amino acid with a positively charged amino (-NH3+) group on its side chain. The -NH2 suffix indicates that the C-terminus of this residue (and thus of the entire peptide) has been modified to an amide (-CONH2) rather than the normal carboxylic acid (-COOH).

Lysine's positive charge contributes to binding interactions with negatively charged regions of the GHSR-1a receptor

The C-terminal amide modification removes the negative charge that a free carboxylic acid would carry, making the overall peptide charge profile more favorable for receptor interaction

C-terminal amides are also more resistant to carboxypeptidase enzymes (which attack the C-terminus of peptides), improving metabolic stability

Putting It Together: Structure-Function Summary

Figure 1: Simplified structure-function map of Ipamorelin's amino acid sequence positions.

The combination of these five residues produces a compact, relatively stable pentapeptide that binds GHSR-1a with sufficient affinity to produce measurable GH release in preclinical models, while the selective structural profile produces less activation of the signaling pathways that lead to cortisol and ACTH release.

How Ipamorelin Is Synthesized: Solid-Phase Peptide Synthesis

What Is SPPS?

Solid-Phase Peptide Synthesis (SPPS) is the standard laboratory method for producing synthetic peptides like Ipamorelin. The key innovation of SPPS (pioneered by Robert Bruce Merrifield, who received the Nobel Prize in Chemistry in 1984 for this work) is that the growing peptide chain is attached to an insoluble solid support (a resin bead) throughout the synthesis, which allows reagents to be added and washed away repeatedly without losing the peptide.

The Fmoc SPPS Process for Ipamorelin

Modern Ipamorelin synthesis uses the Fmoc (fluorenylmethyloxycarbonyl) protection strategy, which is the most widely used method for research peptide production. Here is a simplified summary of the process:

Step 1: Resin preparation The synthesis starts with a resin pre-loaded with the first amino acid (Lys, the C-terminal residue) protected with Fmoc on its alpha-amino group. The resin is the anchor point for the entire growing chain.

Step 2: Deprotection The Fmoc group on the amino acid is removed (deprotected) using a base (typically piperidine in DMF). This exposes the amino group to react with the next incoming amino acid.

Step 3: Coupling The next amino acid in the sequence (D-Phe) is activated using a coupling agent and added to the reaction. It forms a new peptide bond with the exposed amino group of the chain already on the resin. The chain has now grown by one residue.

Step 4: Repeat Steps 2 and 3 are repeated for each amino acid in the sequence, going from C-terminus to N-terminus: D-Phe, then D-2-Nal, then His, then Aib. Each cycle adds one residue to the growing chain.

Step 5: Cleavage and deprotection Once the full five-residue sequence is assembled, the peptide is cleaved from the resin and the protecting groups on amino acid side chains are removed simultaneously using a cleavage cocktail (typically TFA-based).

Step 6: Purification The crude peptide mixture (containing the target Ipamorelin plus synthesis byproducts) is purified by preparative reverse-phase HPLC to achieve 98%+ purity.

Step 7: Lyophilization The purified Ipamorelin solution is frozen and then freeze-dried (lyophilized) to produce the white powder supplied in research vials.

Step 8: Quality control Purity is verified by analytical HPLC and the correct molecular mass is confirmed by mass spectrometry. A certificate of analysis is issued.

For more on quality control methods, see Purity Testing and Quality Control for Ipamorelin Research Peptides.

Research-grade Ipamorelin synthesized to 98%+ purity with third-party CoA documentation is available from Palmetto Peptides for laboratory research use.

Related Research

Complete Guide to Ipamorelin

Ipamorelin Mechanism of Action

Purity Testing and Quality Control for Ipamorelin

Development History of Ipamorelin

Pharmacokinetics of Ipamorelin

Ipamorelin vs GHRP-2 and GHRP-6

Frequently Asked Questions

What is the amino acid sequence of Ipamorelin?

Ipamorelin's sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is a five-residue pentapeptide incorporating two non-natural amino acids and D-forms of two standard amino acids.

What is Aib and why is it in Ipamorelin?

Aib is a non-natural amino acid with two methyl groups on its alpha carbon. It contributes to Ipamorelin's conformational rigidity and resistance to enzymatic degradation, improving its stability as a research compound.

How is Ipamorelin synthesized?

Ipamorelin is produced by solid-phase peptide synthesis (SPPS) using the Fmoc protection strategy. After assembly on a solid resin, the peptide is cleaved, deprotected, purified by HPLC, and lyophilized.

What is Ipamorelin's molecular weight?

Ipamorelin has a molecular weight of 711.87 g/mol and a molecular formula of C38H49N9O5. Its CAS number is 170851-70-4.

Order research-grade Ipamorelin with batch-specific COA from Palmetto Peptides.

Peer-Reviewed Citations

Ankersen M, Johansen NL, Madsen K, Hansen TK, Raun K, Hansen BS, Andersen PH, Thogersen H, Nielsen KK, Peschke B, Lau J, Lundt BF, Sidelmann UG. "Discovery of a new class of functionally and structurally distinct compounds with growth hormone secretagogue properties." Journal of Medicinal Chemistry. 1998;41(19):3699-3704. doi:10.1021/jm980126l

Merrifield RB. "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide." Journal of the American Chemical Society. 1963;85(14):2149-2154. doi:10.1021/ja00897a025

Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

Chan WC, White PD. Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press; 2000.

Final Disclaimer: Ipamorelin is not approved by the FDA for human or veterinary use. All content is for scientific and educational reference only. Palmetto Peptides sells Ipamorelin exclusively for in vitro and preclinical laboratory research.

Authored by the Palmetto Peptides Research Team | Last Updated: March 27, 2026

Related research: sermorelin research.

See Also: Ipamorelin + CJC-1295 Research Guide

See Also: Complete Ipamorelin Research Guide